Form 8-K - Current report:
SEC Accession No. 0001641172-25-016694
Filing Date
2025-06-26
Accepted
2025-06-26 17:15:28
Documents
15
Period of Report
2025-06-25
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 49704
2 EX-3.1 ex3-1.htm EX-3.1 13874
3 EX-99.1 ex99-1.htm EX-99.1 13710
4 GRAPHIC ex99-1_001.jpg GRAPHIC 12415
  Complete submission text file 0001641172-25-016694.txt   270103

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE indp-20250625.xsd EX-101.SCH 3020
6 XBRL LABEL FILE indp-20250625_lab.xml EX-101.LAB 34239
7 XBRL PRESENTATION FILE indp-20250625_pre.xml EX-101.PRE 22362
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3736
Mailing Address 3 COLUMBUS CIRCLE 15TH FLOOR NEW YORK NY 10019
Business Address 3 COLUMBUS CIRCLE 15TH FLOOR NEW YORK NY 10019 (646) 427-2727
Indaptus Therapeutics, Inc. (Filer) CIK: 0001857044 (see all company filings)

EIN.: 863158720 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40652 | Film No.: 251081327
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)